ERBB2 and medulloblastoma: Based on these outcomes, researchers have proposed that direct delivery of HER2-redirected CAR-Ts into the cerebrospinal fluid (CSF) can be investigated in clinical trials with recurring medulloblastoma patients enrolled (104).